American Century Companies Inc. Has $299.48 Million Stock Position in Henry Schein, Inc. $HSIC

American Century Companies Inc. trimmed its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 1.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,512,290 shares of the company’s stock after selling 46,500 shares during the period. American Century Companies Inc.’s holdings in Henry Schein were worth $299,481,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of HSIC. CYBER HORNET ETFs LLC bought a new stake in Henry Schein in the 2nd quarter valued at $25,000. MUFG Securities EMEA plc bought a new stake in Henry Schein in the 2nd quarter valued at $27,000. ANTIPODES PARTNERS Ltd acquired a new stake in Henry Schein during the 2nd quarter valued at $43,000. Sentry Investment Management LLC boosted its position in Henry Schein by 132.1% during the third quarter. Sentry Investment Management LLC now owns 905 shares of the company’s stock worth $59,000 after purchasing an additional 515 shares during the period. Finally, Evelyn Partners Investment Management Services Ltd acquired a new position in Henry Schein in the 2nd quarter valued at $62,000. 96.62% of the stock is owned by institutional investors.

Henry Schein Stock Performance

Shares of Henry Schein stock opened at $82.39 on Friday. Henry Schein, Inc. has a 12 month low of $60.56 and a 12 month high of $89.29. The business’s fifty day simple moving average is $77.85 and its 200 day simple moving average is $72.15. The firm has a market capitalization of $9.45 billion, a P/E ratio of 25.20, a price-to-earnings-growth ratio of 2.41 and a beta of 0.88. The company has a current ratio of 1.38, a quick ratio of 0.79 and a debt-to-equity ratio of 0.59.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.30 by $0.04. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The firm had revenue of $3.44 billion during the quarter, compared to analyst estimates of $3.34 billion. During the same quarter last year, the business earned $1.19 earnings per share. The company’s quarterly revenue was up 7.7% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, analysts anticipate that Henry Schein, Inc. will post 4.74 EPS for the current year.

Insider Buying and Selling at Henry Schein

In other news, CEO Stanley M. Bergman sold 10,785 shares of Henry Schein stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $81.20, for a total transaction of $875,742.00. Following the completion of the sale, the chief executive officer owned 309,092 shares in the company, valued at approximately $25,098,270.40. This trade represents a 3.37% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.08% of the stock is currently owned by insiders.

Henry Schein News Roundup

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Reported quarterly results topped expectations (better EPS and revenue growth), which reinforces momentum in the stable dental market and was a primary driver for the stock rise. Henry Schein beats quarterly profit estimates on stable dental market
• Positive Sentiment: Robert W. Baird upgraded HSIC, reflecting increased analyst confidence in growth/valuation after results. Upgrades can support further upside as they attract buy-side attention. Henry Schein (NASDAQ:HSIC) Upgraded at Robert W. Baird
• Positive Sentiment: Leerink Partners published a bullish note forecasting strong price appreciation, adding to analyst-driven buying pressure. Leerink Partners Forecasts Strong Price Appreciation for Henry Schein (NASDAQ:HSIC) Stock
• Positive Sentiment: Market reaction to the beat pushed HSIC to a new 12‑month high, signaling momentum traders and momentum-based funds may add exposure. Henry Schein (NASDAQ:HSIC) Hits New 12-Month High on Earnings Beat
• Neutral Sentiment: A Yahoo/Finance piece notes analysts are re‑assessing HSIC’s growth profile and valuation — useful context but not an immediate directional catalyst. How Henry Schein (HSIC) Story Is Shifting As Analysts Reassess Growth And Valuation
• Neutral Sentiment: Short‑interest data shows an anomalous report (0 shares / NaN change), which appears to be a reporting/data error and is unlikely to meaningfully affect near‑term trading.
• Negative Sentiment: CEO Stanley M. Bergman sold sizable blocks of stock on Feb. 26–27 (combined sale proceeds ~ $4.0M+), which can be perceived negatively by some investors as profit‑taking or reduced insider conviction. SEC filing: Insider sale filing

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on HSIC. Evercore upped their price target on shares of Henry Schein from $83.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, November 5th. Leerink Partners upped their target price on Henry Schein from $75.00 to $87.00 and gave the company a “market perform” rating in a research report on Tuesday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Henry Schein in a research note on Monday, December 29th. Barclays started coverage on Henry Schein in a research note on Monday, December 8th. They issued an “overweight” rating and a $86.00 price target on the stock. Finally, Robert W. Baird set a $100.00 price objective on shares of Henry Schein and gave the stock an “outperform” rating in a research report on Monday. Six investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $85.58.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.